stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Book value per share
Aurinia Pharmaceuticals Inc's book value per share at the end of fiscal 2025 was 4.3×, up 64.0% from 2.6× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 4.9×. Over the past ten years it has ranged from 0.6× (fiscal 2015) to 4.3× (fiscal 2025) — the current reading is the highest in ten years. Aurinia Pharmaceuticals Inc ranks 158th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 4.3× | 63.96% |
| FY2024 | 2.6× | 0.00% |
| FY2023 | 2.6× | (7.64%) |
| FY2022 | 2.9× | (22.86%) |
| FY2021 | 3.7× | 7.60% |
| FY2020 | 3.4× | 7.22% |
| FY2019 | 3.2× | 141.75% |
| FY2018 | 1.3× | (38.38%) |
| FY2017 | 2.2× | 111.50% |
| FY2016 | 1.0× | 64.08% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 4.9× | 4.25% |
| Jun 2026 | 4.7× | 10.23% |
| Mar 2026 | 4.3× | (0.89%) |
| Dec 2025 | 4.3× | 55.91% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| AUPH Aurinia Pharmaceuticals Inc | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement